Newsfeeds - Spark Newswire

1 minute read

Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years

Today, 8:11 AM

Dermavant Sciences, a Roivant Sciences Ltd. (NASDAQ:ROIV) company, announced results from ADORING 2 Phase 3 study evaluating VTAMA (tapinarof) cream, 1% in…

ROIV

1 minute read

Roivant Announces Phase 3 Trial Of VTAMA Achieved Primary Endpoint And All Secondary Endpoints

By Bill Haddad

Today, 8:11 AM

46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with at

ROIV

1 minute read

Immunovant Could Potentially Be An M&A Target, Writes Analyst

By Vandana Singh

Today, 8:11 AM

Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ:IMVT) with an Overweight rating and a price target of $30. The company’s pipeline includes…

ARGX

1 minute read

Mixed Signals On Valentine’s Day: How Stocks Are Reacting To January Inflation Data

By AJ Fabino

Today, 8:11 AM

Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.

AIN

1 minute read

HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $14 Price Target

By Benzinga Newsdesk

Today, 8:11 AM

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $14 price target.

ROIV

1 minute read

Reported Late Thursday, Roivant Sciences Announces Pricing Of $200M Upsized Public Offering Of 26,666,666 Shares Of Common Stock At A Price Of $7.50/Share

By Happy Mohamed

Today, 8:11 AM

Roivant Sciences (NASDAQ:ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share. All of the common shares to be sold in the offering are to be sold by Roivant.

ROIV

1 minute read

Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $11

By Benzinga Newsdesk

Today, 8:11 AM

Goldman Sachs analyst Corinne Jenkins maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $10 to $11.

ROIV

1 minute read

Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $14

By Benzinga Newsdesk

Today, 8:11 AM

Citigroup analyst Neena Bitritto-Garg maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $11 to $14.

ROIV

1 minute read

Roivant Announces Results From Induction Period Of TUSCANY-2 Phase 2b Study Of RVT-3101; Says ‘RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested’

By Benzinga Newsdesk

Today, 8:11 AM

RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested Across all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates

ROIV

1 minute read

SVB Leerink Maintains Outperform on Roivant Sciences, Raises Price Target to $10

By Benzinga Newsdesk

Today, 8:11 AM

SVB Leerink analyst David Risinger maintains Roivant Sciences (NASDAQ:ROIV) with a Outperform and raises the price target from $8 to $10.

ROIV